HM201 ( DrugBank: - )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
96	クローン病	1
97	潰瘍性大腸炎	1

96. クローン病

---

臨床試験数 : 2,442 /  薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05088369 (ClinicalTrials.gov)	November 11, 2021	12/10/2021	Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201	A First-in-human, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Intravenous Doses of HM201 (Pegylated Human Adrenomedullin) in Healthy Subjects (Adults)	Ulcerative Colitis;Crohn's Disease	Drug: HM201;Drug: Placebo	Syneos Health	Himuka AM Pharma Corp.	Completed	18 Years	55 Years	All	53	Phase 1	Australia

97. 潰瘍性大腸炎

---

臨床試験数 : 2,630 /  薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05088369 (ClinicalTrials.gov)	November 11, 2021	12/10/2021	Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201	A First-in-human, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Intravenous Doses of HM201 (Pegylated Human Adrenomedullin) in Healthy Subjects (Adults)	Ulcerative Colitis;Crohn's Disease	Drug: HM201;Drug: Placebo	Syneos Health	Himuka AM Pharma Corp.	Completed	18 Years	55 Years	All	53	Phase 1	Australia